Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition

Abstract The purpose of our study was to compare two acquired muscle atrophies and the use of myostatin inhibition for their treatment. Myostatin naturally inhibits skeletal muscle growth by binding to the ActRIIB receptor on the cell surface of myofibers. Because blocking myostatin in an adult wild-type mouse induces profound muscle hypertrophy, we applied a soluble ActRIIB receptor to models of disuse (limb immobilization) and denervation (sciatic nerve resection) atrophy. We found that treatment of immobilized mice with ActRIIB prevented the loss of muscle mass observed in placebo treated mice. Our results suggest that this protection from disuse atrophy is regulated by SGK instead of Akt. Denervation atrophy, however, was not protected by ActRIIB treatment, yet resulted in an upregulation of the pro-growth factors Akt, SGK, and components of the mTOR pathway. We then treated the denervated mice with the mTOR inhibitor rapamycin and found that despite a reduction in mTOR activation, there is no alteration of the atrophy phenotype. Additionally, rapamycin prevented the denervation-induced upregulation of the mTORC2 substrates Akt and SGK. Thus, our studies show that denervation atrophy is not only independent from Akt, SGK, and mTOR activation but also has a different underlying pathophysiological mechanism than disuse atrophy.